Abstract
Triple negative breast cancer (TNBC) remains a clinical challenge due to its aggressive nature and the frequent development of resistance to standard chemotherapy. While TNBC is characterized by high glucose consumption, metabolic heterogeneity has historically complicated the use of metabolic inhibitors. This study identifies glucose transporter 1 (GLUT1) as a viable therapeutic target in a specific subset of TNBC. We demonstrate that sensitivity to the GLUT1 inhibitor BAY-876 is dictated by the presence of the retinoblastoma tumor suppressor (RB1). RB1-positive tumors exhibit a strict dependency on glycolysis, whereas RB1-negative tumors utilize metabolic plasticity to survive via oxidative phosphorylation (OXPHOS). These findings establish RB1 protein expression as a critical companion biomarker for GLUT1-targeted therapies.
Introduction
Triple Negative Breast Cancer (TNBC) is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 amplification. This lack of traditional targets leaves patients with limited options, primarily cytotoxic chemotherapy. Although TNBC cells often exhibit the "Warburg effect"—a preference for glycolysis even in the presence of oxygen—targeting this metabolic addiction has been difficult because not all TNBC tumors respond uniformly to glucose deprivation.
By investigating the expression of SLC2A1 (the gene encoding GLUT1), researchers identified a significant metabolic dependency in basal-like TNBC. This study sought to validate GLUT1 inhibition as a strategy and, crucially, to identify a biomarker that can predict which patients will benefit from such an intervention.
Methodology
The research team utilized a multi-layered experimental framework to evaluate the efficacy of GLUT1 inhibition:
- Pharmacological and Genetic Tools: The study employed BAY-876, a highly selective and potent GLUT1 inhibitor, alongside siRNA and shRNA techniques to silence the SLC2A1 gene.
- Bioenergetic Assessment: Using Seahorse XF technology, the researchers measured the Extracellular Acidification Rate (ECAR) and Oxygen Consumption Rate (OCR) to map the metabolic profiles of various cell lines.
- Advanced Preclinical Models: To ensure clinical relevance, the team used Patient-Derived Organoids (PDXDOs) and 3D tumor explants (PDXDEs) cultured on gelatin sponges, preserving the original tumor architecture and heterogeneity.
- Integrative Omics: Transcriptomic (RNA-seq) and proteomic data from cohorts like TCGA, METABRIC, and the Princess Margaret Cancer Centre were analyzed to identify pathways associated with drug sensitivity.
The RB1-GLUT1 Metabolic Axis
The study’s central discovery is the role of the retinoblastoma tumor suppressor (RB1) in regulating metabolic vulnerability. RB1-positive TNBC cells appear "locked" into a glycolytic state, making them highly susceptible to GLUT1 inhibition. When GLUT1 is blocked in these cells, they are unable to generate sufficient energy, leading to growth arrest and apoptosis.
Conversely, RB1-negative cells exhibit significant metabolic plasticity. When their primary glucose transport is inhibited, these cells act as "metabolic chameleons," rapidly switching their energy production to oxidative phosphorylation (OXPHOS), often fueled by glutamine. This flexibility allows them to bypass the blockade and survive treatment.
Key Findings
- Predictive Biomarker: RB1 protein levels, rather than just genetic status, showed a strong correlation ($R^2 = 0.73$) with sensitivity to BAY-876. High RB1 expression predicted a positive response to the drug.
- Pathway Signatures: High activity in the E2F target pathway—a hallmark of RB1 loss—was identified as a molecular signature for metabolic flexibility and resistance to GLUT1 inhibitors.
- Functional Validation: The researchers successfully reversed drug sensitivity in the lab. Overexpressing RB1 in resistant (RB1-negative) cells rendered them sensitive to BAY-876, while knocking down RB1 in sensitive cells induced resistance by enabling the OXPHOS metabolic switch.
- Ex Vivo Success: In patient-derived explants, 70% of RB1-positive cases responded to BAY-876 with significant cell death and growth inhibition, whereas RB1-negative explants remained unaffected.
Discussion and Clinical Implications
The identification of the RB1-GLUT1 axis provides a clear path forward for stratifying TNBC patients. Rather than treating TNBC as a monolithic disease, clinicians could use standard immunohistochemistry (IHC) to measure RB1 protein levels and identify candidates for GLUT1-targeted therapy.
However, the study also highlights the challenge of intra-tumoral heterogeneity. Tumors containing a mix of RB1-positive and RB1-negative cells may only partially respond, potentially leading to the emergence of resistant populations. To combat this, the authors suggest a "one-two punch" approach: combining GLUT1 inhibitors with OXPHOS or glutaminase inhibitors to eliminate the metabolic backup plans used by RB1-negative cells.
In conclusion, this research warrants the clinical evaluation of GLUT1 inhibitors like BAY-876 in TNBC patients, specifically those stratified by RB1 expression, offering a more personalized approach to a notoriously difficult-to-treat cancer.
Summary updated